Vaxart Inc (VXRT)

OTHER OTC:VXRT

VXRT

Vaxart

RESEARCH TOOLSreports

Want to see VXRT full AI Analyst Report?

Vaxart (VXRT) Price & Analysis

4,427 Followers

VXRT Stock Chart & Stats

$0.36

-$0.02(-2.57%)

At close: Jan 08 4:00 PM EST

$0.36

-$0.02(-2.57%)

Day’s Range― - ―

52-Week Range$0.26 - $0.84

Previous CloseN/A

Volume1.40M

Average Volume (3M)452.67K

Market Cap

$179.85M

Enterprise Value$135.36M

Total Cash (Recent Filing)$63.81M

Total Debt (Recent Filing)$8.98M

Price to Earnings (P/E)0.4

Beta1.82

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding241,414,050

10 Day Avg. Volume338,587

30 Day Avg. Volume452,665

Financial Highlights & Ratios

PEG Ratio-0.03

Price to Book (P/B)0.92

Price to Sales (P/S)0.34

P/FCF Ratio10.65

Enterprise Value/Market Cap0.75

Enterprise Value/Revenue0.57

Enterprise Value/Gross Profit0.63

Enterprise Value/Ebitda4.80

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe Phase II COVID-19 vaccine trial is progressing rapidly, with the sentinel cohort enrollment ahead of schedule, indicating strong advancement in the study.

Growth PotentialVaxart's efforts to refine its norovirus program address a significant unmet need in a market with no approved vaccines, showcasing potential for growth and innovation.

Regulatory MilestonesVXRT's norovirus oral vaccine unique competitive position to further benefit from upcoming regulatory milestones.

Vaccine DevelopmentVaxart advances with $453M BARDA-backed COVID-19 vaccine, poised to lead in mucosal immunity.

Bears Say

Investor PerceptionInvestor perception of the norovirus opportunity has considerable room for improvement given the significant disease burden and the lack of approved or late-stage programs.

Vaxart News

Vaxart Adds Veteran Biotech Leader to Board

The latest announcement is out from Vaxart ( ($VXRT) ). On April 23, 2026, Vaxart, Inc., a clinical-stage...

14d ago

VXRT

Vaxart Expands Utah Avenue Space, Consolidates South SF Footprint

Vaxart ( ($VXRT) ) just unveiled an announcement. On April 20, 2026, Vaxart, Inc. amended its lease agreement...

17d ago

VXRT

Vaxart Secures Flexible $25 Million Equity Purchase Facility

The latest announcement is out from Vaxart ( ($VXRT) ). On April 16, 2026, Vaxart, Inc. entered into...

21d ago

VXRT

Vaxart Earnings Call: Big Deals, Bigger Expectations

Vaxart (($VXRT)) has held its Q4 earnings call. Read on for the main highlights of the call. Vaxart’s...

2M ago

VXRT

Is VXRT a Buy, Before Earnings?

Vaxart (VXRT) is scheduled to report 4th quarter earnings on 03/12/2026, after the market closes. Regarding Q4 estimates,...

2M ago

VXRT

One new option listing and option delistings on January 20th

New option listings for January 20th include Telefonica S.A. (TELFY). Option delistings effective January 20th include MSCI USA...

4M ago

CVM

TEF

Vaxart announces publication in npj Vaccines on norovirus candidate

Vaxart (VXRT) announced the publication in npj Vaccines of data from a double-blind, placebo-controlled Phase 1 trial evaluating...

4M ago

VXRT

Vaxart to Relocate Headquarters Amid Lease Termination

Vaxart ( ($VXRT) ) has shared an announcement. On December 18, 2025, Vaxart, Inc. entered into a termination...

4M ago

VXRT

Vaxart’s Earnings Call: Dynavax Partnership and Revenue Surge

Vaxart (($VXRT)) has held its Q3 earnings call. Read on for the main highlights of the call. Vaxart’s...

6M ago

VXRT

Vaxart’s Strategic Moves and Financial Highlights

Vaxart ( ($VXRT) ) has released its Q3 earnings. Here is a breakdown of the information Vaxart presented...

6M ago

VXRT

Options Volatility and Implied Earnings Moves Today, November 13, 2025

Today, several major companies are expected to report earnings: Applied Materials (AMAT), Ballard Power Systems (BLDP), Walt Disney...

6M ago

Is VXRT a Buy, Before Earnings?

Vaxart (VXRT) is scheduled to report 3rd quarter earnings on 11/13/2025, after the market closes. Regarding Q3 estimates,...

6M ago

VXRT

Dynavax enters license agreement for Vaxart’s oral COVID-19 vaccine program Vaxart

Dynavax Technologies (DVAX) and Vaxart (VXRT) announced that they have entered into an exclusive, worldwide license and collaboration...

6M ago

DVAX

VXRT

Vaxart wthdraws reverse stock split proposal

Vaxart (VXRT) has withdrawn its reverse stock split proposal. “After careful consideration, we have decided to officially withdraw...

8M ago

VXRT

VXRT FAQ

What was Vaxart Inc’s price range in the past 12 months?

Vaxart Inc lowest stock price was $0.26 and its highest was $0.84 in the past 12 months.

What is Vaxart Inc’s market cap?

Vaxart Inc’s market cap is $179.85M.

When is Vaxart Inc’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Vaxart Inc’s earnings last quarter?

Currently, no data Available

Is Vaxart Inc overvalued?

According to Wall Street analysts Vaxart Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Vaxart Inc pay dividends?

Vaxart Inc pays a Notavailable dividend of $12.188 which represents an annual dividend yield of N/A. See more information on Vaxart Inc dividends here

What is Vaxart Inc’s EPS estimate?

Vaxart Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Vaxart Inc have?

Vaxart Inc has 241,414,050 shares outstanding.

What happened to Vaxart Inc’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Vaxart Inc?

Currently, no hedge funds are holding shares in VXRT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Vaxart Stock Smart Score

Neutral

Fundamentals

Return on Equity

33.83%

Trailing 12-Months

Asset Growth

14.47%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.